CURE® Speaking Out Launches Video Series in Recognition of National Prostate Cancer Awareness Month


Charles J. Ryan, M.D., internationally recognized for his research on prostate cancer, discusses risk factors, treatments and racial disparities associated with the disease.

better-informedIn support of National Prostate Cancer Awareness Month, the CURE® Speaking Out video series has revealed a five-episode discussion titled, "Discussing Trends in Prostate Cancer," featuring Charles J. Ryan, M.D., professor of medicine and director of the division of hematology, oncology and transplantation at the University of Minnesota. Ryan is a member of the ZERO - The End of Prostate Cancer medical advisory board.

“We are honored to have Dr. Charles Ryan partake in our educational series to increase awareness of and help prevent prostate cancer,” said Mike Hennessy Jr., president, and CEO of MJH Life Sciences™, parent company of CURE Media Group. “These expert video clips are an incredible resource, and we encourage our viewers and readers to share with patients, caregivers and survivors.”

During this series, Ryan discusses a variety of topics related to prostate cancer. In the first episode, he provides an overview of the basics of the disease, including signs, symptoms, and risk factors. In the following episodes, Ryan reviews the differences between genetics and genomics in prostate cancer, treatment options for men with advanced disease and how the COVID-19 pandemic has affected individuals, while also addressing racial disparities associated with prostate cancer.

“I am delighted to work with CURE and ZERO to address some of the common concerns faced by men who are recently diagnosed with prostate cancer as well as those who have been receiving treatment for many years,” said Ryan. “My hope is that those who listen to this series are able to be better informed patients with their doctors, have a deeper understanding of their own unique set of situations with this disease, and to alleviate some of the natural and expected anxieties of being a cancer patient.”

Jamie Bearse, CEO of ZERO added, “By providing educational resources and expert insights, patients can become better equipped in making informed decisions regarding their treatment and cancer care. Tools like this video series help empower patients to be their own best advocates."

CURE® Speaking Out is a video platform designed to offer patients, caregivers, and advocates as much information as possible for their cancer journey. In parallel with its print columns, CURE™ provides patients and caregivers with firsthand information from experts in the field. Throughout each video series, CURE® works with leading cancer advocacy groups to offer advice and assistance to individuals across various cancer types, as well as their caregivers, advocates, and health care professionals, to provide cancer updates, research, and education.

To view the complete video series, click here.

About CURE Media Group

CURE Media Group is the leading resource for cancer updates, research and education. It features a full suite of media products, including the industry-leading website,; innovative video programs, such as “CURE Connections®,” a series of widely attended live events; CURE® magazine, which reaches more than 1 million readers; and the dynamic website for oncology nurses,, and its companion publication, Oncology Nursing News®. CURE Media Group is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channels.
Related Videos
Alicia Morgans, MD, MPH, an expert on prostate cancer
Reginald Tucker-Seeley, MA, ScM, ScD, an expert on prostate cancer
Rashid K. Sayyid, MD, MSc, an expert on prostate cancer
Reginald Tucker-Seeley, MA, ScM, ScD, an expert on prostate cancer
Alicia Morgans, MD, MPH, an expert on prostate cancer
Alicia Morgans, MD, MPH, an expert on prostate cancer
Dr. Psutka in an interview with CURE
Dr. Alicia Morgans in an interview with CURE